What Is Ipamorelin?

Ipamorelin is a five-amino-acid growth hormone-releasing peptide (GHRP) that selectively stimulates the pituitary gland to release growth hormone without significantly affecting cortisol, prolactin, or appetite . It was developed in the late 1990s as a cleaner alternative to earlier GHRPs like GHRP-6 and GHRP-2.

Ipamorelin is not FDA-approved for any medical condition. It is available through compounding pharmacies under physician supervision. For a full overview, see our Ipamorelin benefits guide.

How Delivery Method Affects Ipamorelin

The way a peptide enters your body determines how much of it actually reaches the target tissues and produces a biological effect. This concept is called bioavailability, and it is the central issue in the oral vs injection debate.

The Oral Route: Challenges for Peptides

Peptides are chains of amino acids held together by peptide bonds. When you swallow a peptide, it enters the gastrointestinal tract, where it encounters:

• Stomach acid: The low pH of the stomach (around 1.5 to 3.5) can denature the peptide structure, reducing or eliminating its biological activity.
• Digestive enzymes: Proteases like pepsin in the stomach and trypsin in the small intestine are specifically designed to break peptide bonds. These enzymes treat ipamorelin the same way they treat dietary protein .
• First-pass metabolism: Any peptide that does survive digestion must pass through the liver before reaching systemic circulation. The liver further metabolizes and clears peptide fragments.

The result is that oral bioavailability for most injectable peptides, including ipamorelin, is estimated at less than 1 to 2 percent . This means that a 300 mcg oral dose might deliver less than 3 to 6 mcg of active peptide to the bloodstream.

The Injection Route: Direct Delivery

Subcutaneous injection places the peptide directly into the tissue beneath the skin, where it is absorbed into the bloodstream through local capillary networks. This route avoids the entire digestive system and liver first-pass effect.

Subcutaneous bioavailability for ipamorelin is estimated at approximately 90 to 100 percent, meaning nearly the entire administered dose reaches circulation in its active form . Absorption typically occurs within 15 to 30 minutes, producing a predictable and measurable growth hormone pulse.

Side-by-Side Comparison

What About Oral Peptide Technology?

Some companies market oral peptide products using advanced delivery technologies such as:

• Enteric coatings: Capsule coatings that resist stomach acid and dissolve in the small intestine.
• Absorption enhancers: Compounds like sodium caprate or SNAC that temporarily increase intestinal permeability.
• Nanoparticle encapsulation: Microscopic carriers designed to protect peptides during digestion.

While these technologies have shown promise for certain peptides (most notably oral semaglutide, which uses the SNAC absorption enhancer), they have not been validated for ipamorelin specifically . Oral semaglutide required years of pharmaceutical development and enormous doses to achieve meaningful oral bioavailability, and it is a very different molecule from ipamorelin.

Until peer-reviewed research demonstrates that oral ipamorelin formulations can produce reliable, dose-dependent growth hormone release, subcutaneous injection remains the evidence-based standard.

Dosing and Administration

Because injection is the recommended route, here are key administration guidelines:

• Standard dose: 200 to 300 mcg per injection, administered 1 to 3 times daily
• Timing: Administer on an empty stomach, ideally before bed or first thing in the morning. Avoid eating for 30 minutes after injection.
• Injection method: Subcutaneous injection using an insulin syringe. Rotate injection sites between the lower abdomen, outer thigh, and upper arm.
• Reconstitution: Ipamorelin comes as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before use. See our Ipamorelin how to reconstitute guide for detailed instructions.

For complete injection guidance, visit our Ipamorelin how to inject guide.

Benefits and Expected Results

When administered via subcutaneous injection, ipamorelin may support:

• Increased growth hormone release in a natural pulsatile pattern
• Improved sleep quality and deeper restorative sleep
• Gradual improvements in body composition
• Faster recovery from exercise and physical stress
• Better skin hydration and collagen production
• Enhanced joint comfort and connective tissue health

These benefits are supported by research conducted exclusively with injectable formulations. There is no clinical evidence that oral ipamorelin produces comparable outcomes.

Side Effects and Safety

Ipamorelin administered via subcutaneous injection has a favorable safety profile. Common side effects are mild and may include:

• Mild headache (usually resolves within the first week)
• Transient flushing after injection
• Injection site redness or minor irritation
• Mild water retention
• Tingling in extremities (temporary)

Oral formulations may carry additional risks related to unverified delivery technologies, unknown excipients, and unpredictable absorption patterns. We recommend avoiding unregulated oral peptide products.

For detailed safety information, see our Ipamorelin side effects guide.

Who Is a Good Candidate?

Adults interested in ipamorelin therapy should work with a physician who can prescribe pharmaceutical-grade injectable formulations from a licensed compounding pharmacy. Good candidates are typically:

• Adults over 30 experiencing age-related GH decline
• Individuals seeking support for body composition, recovery, or sleep
• People comfortable with self-administered subcutaneous injections (or willing to learn)
• Patients who have been medically evaluated and cleared for peptide therapy

Ipamorelin is not recommended for individuals who are pregnant or nursing, have active cancer, or have certain metabolic disorders. Your physician will review your complete medical history.

Frequently Asked Questions

Can I take ipamorelin as a pill or capsule?

While some companies sell oral ipamorelin products, there is no clinical evidence that oral ipamorelin achieves meaningful bioavailability or produces reliable growth hormone release. Subcutaneous injection is the only delivery method supported by research.

Why is oral ipamorelin so much less effective?

Ipamorelin is a small peptide that is rapidly degraded by digestive enzymes and stomach acid. Less than 1 to 2 percent of an oral dose is estimated to reach the bloodstream in active form.

Are sublingual ipamorelin products any better?

Sublingual (under the tongue) delivery avoids stomach acid but still faces enzymatic degradation from salivary enzymes and limited absorption through the oral mucosa. There is no peer-reviewed evidence that sublingual ipamorelin achieves clinically meaningful GH release.

Is the injection painful?

Subcutaneous injections use very small needles (typically 29 to 31 gauge insulin syringes) and are described by most users as causing minimal discomfort, often less than a mosquito bite. The technique is easy to learn and becomes routine quickly.

Where can I get pharmaceutical-grade injectable ipamorelin?

Pharmaceutical-grade ipamorelin is available through licensed compounding pharmacies with a physician prescription. Form Blends can connect you with a licensed provider to determine if ipamorelin is appropriate for you.